Rigel Pharmaceuticals Stock News

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

Rigel Pharmaceuticals (RIGL) shares closed today at 1.8% above its 52 week low of $2.72, giving the company a market cap of $473M. The stock is currently down 20.9% year-to-date, down 5.5% over the past 12 months, and down 2.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 51.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 13.7% The company's stock price performance over the past 12 months beats the peer average by -29.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

During the last session, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)s traded shares were 0.88 million, with the beta value of the company hitting 1.38. At the end of the trading day, the stocks price was $2.92, reflecting an intraday gain of 2.46% or $0.07. The 52-week high for the RIGL share is $5.50, that puts it down Do You Still Have A Reason To Buy Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) After A 6.18% Jump In The Last Week? Read More »

California State Teachers Retirement System decreased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 235,702 shares of the biotechnology companys stock after selling 20,529 shares during the quarter. California State Teachers Retirement Systems holdings []

Equities analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $23.22 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Rigel Pharmaceuticals earnings. The lowest sales estimate is $22.96 million and the highest is $23.48 million. Rigel Pharmaceuticals reported sales of $18.45 million during the same quarter last year, []

Brokerages predict that Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) will report sales of $23.22 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Rigel Pharmaceuticals earnings. The highest sales estimate is $23.48 million and the lowest is $22.96 million. Rigel Pharmaceuticals posted sales of $18.45 million in the same quarter last []

Northern Trust Corp lessened its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 3.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,799,267 shares of the biotechnology companys stock after selling 71,354 shares during the quarter. Northern Trust Corp owned about []

WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts….

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q3 2021 Results - Earnings Call Transcript

Rigel (RIGL) delivered earnings and revenue surprises of -20.00% and -10.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close o

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dea

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety o